|Day Low/High||17.31 / 17.75|
|52 Wk Low/High||2.35 / 23.34|
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
After its recent run, it appears to be headed for its next price target.
The only big move was a stumble in volatility, but equities failed to take advantage.
But trust levels are very low since we haven't managed to bounce at all the past week.
The sector is seeing strong revenue, and Jazz and Amarin have the charts to match.
Breadth is very negative, and the big market picture is not attractive at all.
I'm not looking to hold a lot over the weekend, so I'm focused on the short term.